Walvax Biotechnology Co Ltd
Research Walvax Biotechnology Co Ltd (300142.SZ) on Bullrun: market cap CNY 17.85B, P/E 1116.0, dividend yield 1.4%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker300142.SZ
- ExchangeSZ
- CountryChina
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyCNY
- Market capCNY 17.85B
- P/E1116.0
- Dividend yield1.4%
- Financial periodQ2 2026
- RevenueCNY 390.37M
- Net income-CNY 56.48M
- Free cash flowCNY 127.35M
- Gross margin69.2%
Valuation Snapshot
latest market cap is CNY 17.85B; P/E is 1116.0; dividend yield is 1.4%.
Peer valuation comparison
Latest P/E is 1116x versus a Healthcare sector median of 21.8x (5020.4% above).
Latest dividend yield is 1.38% versus a Healthcare sector median of 2.4% (42.5% below).
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-11-11 | CNY 17.85B | 1116.0 | 1.4% | 0.16 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0.16 CNY, yield 1.4%.
About Walvax Biotechnology Co Ltd
Walvax Biotechnology Co., Ltd., engages in the research and development, manufacture, and distribution of vaccines in China and internationally.
ETFs that hold Walvax Biotechnology Co Ltd
US-listed ETFs
Walvax Biotechnology Co Ltd is held by 18 US-listed ETFs, going by the latest portfolios they filed with the SEC. The 8 most traded of them:
| ETF | Weight | Fee |
|---|---|---|
| Vanguard Total International Stock Index Fund ETF Shares (VXUS) | <0.01% | 0.05% |
| Vanguard FTSE Emerging Markets Index Fund ETF Shares (VWO) | <0.01% | 0.06% |
| Vanguard Total World Stock Index Fund ETF Shares (VT) | <0.01% | 0.06% |
| Vanguard FTSE All-World ex-US Index Fund ETF Shares (VEU) | <0.01% | 0.04% |
| Schwab Emerging Markets Equity ETF (SCHE) | <0.01% | 0.06% |
| State Street SPDR Portfolio Emerging Markets ETF (SPEM) | <0.01% | 0.07% |
| Dimensional Emerging Core Equity Market ETF (DFAE) | <0.01% | 0.29% |
| Dimensional Emerging Markets Core Equity 2 ETF (DFEM) | <0.01% | 0.39% |
Portfolios as filed with the SEC on Form N-PORT, dated May to July 2026. Brokers in the EU generally do not offer US-listed ETFs to retail investors.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Walvax Biotechnology Co Ltd's market cap?
Walvax Biotechnology Co Ltd's market capitalization is CNY 17.85B.
What is Walvax Biotechnology Co Ltd's P/E ratio?
Walvax Biotechnology Co Ltd's price-to-earnings (P/E) ratio is 1116.0.
Does Walvax Biotechnology Co Ltd pay a dividend?
Walvax Biotechnology Co Ltd has a dividend yield of 1.4%.
What does Walvax Biotechnology Co Ltd do?
Walvax Biotechnology Co., Ltd., engages in the research and development, manufacture, and distribution of vaccines in China and internationally. Its vaccine portfolio includes recombinant human papillomavirus bivalent, 13-valent pneumococcal polysaccharide conjugate, 23-valent pneumococcal polysaccharide, group ACYW135 meningococcal polysaccharide, group A and C meningococcal polysaccharide, group A and group C meningococcal conjugate, and haemophilus influenzae type b conjugate vaccines, as well as diphtheria, tetanus and acellular pertussis combined vaccine.